Ethics & Clinical Trials

1. The 14-Day Rule

In 1979, a UK government committee chaired by Mary Warnock proposed a limit on in vitro embryo research: no embryo would be cultured beyond 14 days after fertilisation, corresponding to the onset of primitive streak formation and the first differentiation of the embryonic and extra-embryonic lineages. The rationale was twofold: the primitive streak marks the earliest point at which twinning is no longer possible (so individuation begins), and central nervous system development starts shortly after. The Warnock Report’s recommendation became UK law in 1990 (Human Fertilisation and Embryology Act) and was adopted in most jurisdictions that regulate embryo research.

For three decades the limit was theoretical, because no one could culture embryos past day 7 or 8. Then Magdalena Zernicka-Goetz and Ali Brivanlou in 2016 published protocols that pushed culture to day 12–13. The 14-day limit suddenly became binding. The ISSCR (International Society for Stem Cell Research) updated its guidelines in 2021 to allow extension of research beyond 14 days with case-by-case ethical review, reflecting a shift in consensus.

Synthetic embryo models (blastoids, gastruloids, ETS/ETX embryos; Rivron 2018, Amadei 2022) have created a further wrinkle: these are not embryos derived from gametes, so the 14-day rule does not obviously apply, but they recapitulate many features of early development. Regulation is adapting in real time.

2. The ESC Controversy and the iPSC Workaround

Human ESC derivation necessarily destroys a blastocyst. For the religious and political constituencies that consider blastocysts morally equivalent to children, this is an insuperable objection. In the USA, the Dickey-Wicker Amendment (1996) prohibits federal funding of research that destroys human embryos; the George W. Bush administration (2001) limited federal funding to pre-existing hESC lines; the Obama administration partially reversed this in 2009. Europe is mixed: Germany, Austria, and Italy restrict hESC work; the UK and Sweden are permissive.

Yamanaka’s 2006 iPSC work dissolved most of this controversy — iPSCs can be generated from patient skin biopsies without touching an embryo. Essentially all current clinical programmes use iPSCs. The remaining argument for continued hESC work: some cell types may differentiate better from primed-state hESCs than from iPSCs, and comparative controls require both. In practice, iPSCs now dominate.

3. Germline Modification and Heritable Genome Editing

A distinct ethical arena: modifications to the germline (sperm, egg, embryo) are inherited. Most countries prohibit germline editing for reproduction. The 2018 He Jiankui affair — a Chinese researcher who CRISPR-edited twin embryos at CCR5 and brought them to term — triggered international condemnation, a Chinese criminal conviction (three-year sentence), and a research-community moratorium.

Mitochondrial replacement therapy (“three-parent IVF”) is a narrow exception — UK-legal since 2015, first UK babies born 2023 — for preventing transmission of severe mtDNA disease. See the Mitochondria coursefor details. The 14-day rule, no-pregnancy restrictions on edited embryos, and jurisdictional variability in what is allowed form a complex regulatory landscape that the field navigates case by case.

4. Clinical Trial Regulation

Cell and gene therapies are regulated as biologics. In the US, the FDA’s Center for Biologics Evaluation and Research (CBER) oversees cell-therapy INDs. Key considerations distinct from small-molecule drugs:

• Identity & potency: certifying that a manufactured iPSC-derived cell product is indeed the target cell type requires extensive flow-cytometry and functional assays.
• Tumorigenicity: the stringent test — residual pluripotent cells can form teratomas — requires sensitive quantitative assays for Oct4/Nanog positivity, often combined with karyotyping and driver-mutation screening.
• Comparability: cell-based products are biologically variable batch-to-batch; demonstrating that a clinical-scale lot is equivalent to the preclinical-scale lot is a nontrivial statistical exercise.
• Immune matching: allogeneic products require HLA matching or host immunosuppression; autologous avoids these but raises cost and manufacturing lead-time issues.
• Durability & long-term follow-up: the FDA requires 15-year follow-up for integrating gene therapies and many iPSC-derived cell products.

Japan introduced a distinctive accelerated-approval pathway (Pharmaceuticals, Medical Devices and Other Therapeutic Products Act, 2014) under which regenerative products can receive conditional approval after Phase 2, with mandatory post-market evidence generation. This enabled rapid approval of several autologous cell products (HeartSheet, JACE). The EU’s ATMP regulation covers similar ground more conservatively; the US has Regenerative Medicine Advanced Therapy (RMAT) designation.

5. Unregulated Clinics & “Stem-Cell Tourism”

A large and predatory industry has emerged offering unregulated “stem-cell” treatments for osteoarthritis, spinal injuries, autism, ALS, COPD, sports injuries, and dozens of other conditions without approval or evidence. Most use adipose- or bone-marrow-derived minimally-processed stromal preparations — technically not stem cells under the strict definition, usually termed “mesenchymal stromal cells.” Turner & Knoepfler (2016) catalogued >570 US clinics in unregulated operation; the number has since grown. Annual US revenue estimated at >$2 billion.

Serious adverse events have been documented: blindness after intravitreal adipose-derived injections (three patients, Florida 2017); tumour growth after “regenerative” intrathecal injections; deaths from untested intravenous products. The FDA has issued warning letters and sought court injunctions against the most egregious, but enforcement has been uneven.

The problem is exacerbated by medical tourism — clinics in Mexico, Panama, the Cayman Islands, and Ukraine explicitly market to US and European patients with conditions for which no approved cell therapy exists. The ISSCR maintains a public resource (A Closer Look at Stem Cells) with patient-facing guidance. Rigorously distinguishing “stem cell” therapy from the unregulated industry is one of the ongoing responsibilities of the field.

6. Access and Equity

Approved stem-cell and gene therapies are extraordinarily expensive. Casgevy (2023) is priced at $2.2M per patient; Zynteglo at $2.8M; Strimvelis was ~€594 000 in the EU; CAR-T therapies range $375 000–$500 000 plus hospitalisation. These prices reflect development costs amortised over rare-disease patient populations, complex autologous manufacturing, and monopoly pricing in the absence of competition. Global access is severely restricted — perhaps 5% of eligible sickle-cell patients worldwide can afford Casgevy. Policy innovations under discussion include risk-sharing outcome-based contracts, generic / biosimilar pathways for cell products, and price negotiation through public payers (Medicare, NHS). The promise of stem-cell medicine is, presently, a promise the global health system cannot yet honour.

7. The Road Forward

The field has travelled from the Till-McCulloch 1961 spleen colony assay to clinical iPSC-derived pancreatic islets curing type-1 diabetes in sixty years — a single scientific generation. The next decade will likely see (a) expansion of HSC gene therapies to autoimmune disease, (b) first-generation iPSC cell therapies for common diseases (AMD, Parkinson’s, type-1 diabetes) reaching approval, (c) in vivo HSC gene editing replacing ex vivo ones, (d) brain organoids contributing to drug discovery for neurodevelopmental and neurodegenerative disease, and (e) cost reductions via scaled iPSC banks and hypoimmune universal cell lines. A student finishing this course is equipped to follow any of these developments in the primary literature — and, increasingly, to contribute to them.